Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
Financials
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Share Price History
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
(1)
About
Mankind Pharma Ltd.
NSE: MANKIND
|
BSE: 543904
|
ISIN: INE634S01028
|
Industry: Pharmaceuticals
|
Expensive Performer
2427.7000
5.80
(
0.24
%)
NSE
Apr 03, 2025
15:31 PM
27.70% Gain from 52W Low
Volume:
446.5K
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Mankind Pharma Ltd.
12 Mar 2025
2427.70
0.24%
Mankind Pharma Launches Generic Version Of Empagliflozin Diabetes Medication
NDTV Profit
The launch follows the expiration of Boehringer Ingelheim's patent for Empagliflozin in India.
Geojit BNP Paribas released a Accumulate report for Mankind Pharma Ltd. with a price target of 2691.0 on 26 Mar, 2025.
More from Mankind Pharma Ltd.
Recommended
Market closes lower, Bank of Baroda's deposits rise 9.3% YoY in Q4FY25
Trendlyne Marketwatch |
03 Apr 2025, 03:57PM
Chart of the Week: Drop in multibagger stocks from 157 in FY24 to 18 in FY25
The Baseline |
03 Apr 2025, 01:40PM
Former multibaggers: The top ten disappointments of FY25
The Baseline |
02 Apr 2025, 07:20PM